NCT00963183 - AZD5423 Single Ascending Dose Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Healthy Volunteers

Interventions

DRUG

AZD5423

Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.

DRUG

Placebo

Solution for nebulisation, inhaled. Each subject will receive a single-dose.

Trial Locations (1)

Unknown

Research Site, London